Kilkivan Farmer Pins Hope on National MND Clinical Trial

Motor neurone disease is set to advance to a national Phase 2 clinical trial targeting 75 participants across six Australian sites.

Julianne McLean, a 49-year-old cattle farmer from Kilkivan located about 230 kilometres north of Brisbane, received her diagnosis of motor neurone disease, also known as amyotrophic lateral sclerosis, in August.

The condition causes progressive degeneration of nerve cells in the brain and spinal cord that control movement, according to Antony Winkel, Sunshine Coast University Hospital director of neurology and NuNerve clinical lead. Dr Winkel has worked in neurology for more than eight years and treats Queensland patients including Ms McLean.

“It’s one of those really nasty diseases where it doesn’t matter what you do, you know the next day is going to be harder in some way,” Dr Winkel said, adding that the condition carries a typical life expectancy of two to three years post-diagnosis.

The 75-person trial builds on more than 25 years of research from The University of Queensland’s Queensland Brain Institute. The university’s commercialisation company, UniQuest, and the Estate Peter Goodenough Unit Trust established the biotechnology company NuNerve to advance the findings. Emeritus Professor Perry Bartlett and Andrew Boyd originated the research at the institute, focusing on how nerve cells communicate and repair themselves.

NUN-004 Protein Therapy

The trial will test a protein-based therapy designated as NUN-004 across medical sites in the Sunshine Coast, Sydney, Newcastle, Brisbane, and Perth. Professor Bartlett, who serves as NuNerve chair and chief scientific officer, said the molecule inhibits the EphA4 receptor, which links to motor neuron degeneration and impaired neural connection recovery.

Hmbs qbi nunerve trial perry bartlett
Photo: news.uq.edu.au

“No approved treatment has been shown to halt or reverse progression across the broad MND population,” Professor Bartlett said. “NUN-004 was designed to go further to protect motor neurons and create the conditions for damaged neural connections to repair.”

During the initial six-month phase involving eight participants, some individuals showed signs of stabilised conditions alongside reported improvements in walking, balance, grip, and strength.

Dr Winkel said that the Phase 2 trial will measure everyday function alongside respiratory, neurophysiological, and biomarker assessments to verify whether those early signals represent a genuine treatment effect. UniQuest CEO Dean Moss said that advancing the drug represents a major milestone in translating long-term university research into clinical testing.

Trial rollout offers hope for patients with limited options

For patients like Ms McLean, who has spent over 20 years farming cattle and crops with her husband Angus, the disease has halted physical work on the property.

“Anytime you’re given a terminal diagnosis and that there’s officially no cure, the first thing that you lose is hope,” Ms McLean said.

MND Queensland chief executive Stacey Thorpe described the trial rollout as an encouraging development that offers genuine reasons for hope in a field with limited treatment options. While safety and effectiveness remain to be established through the upcoming trial, Ms McLean said the focus remains on spending time with her husband and teenage daughters.

“Once you know you have limited time, yes, there’s a gift in that you do choose to spend it a lot more wisely on things that truly do matter,” Ms McLean said.

Phase 2 trial recruits 75 participants across Australia

What causes motor neurone disease?

“Currently, we don't have a great understanding of what causes it,” Dr Winkel said.

How many participants are joining the Phase 2 trial?

The trial will recruit 75 participants across six clinical sites in Australia.

Queensland, where the trial spans sites from the Sunshine Coast to Brisbane, is Australia’s second-largest state by area at 1,723,030 square kilometres and the third-most-populous with over 5.7 million residents. Separated from New South Wales as a self-governing colony on 6 June 1859, it became a founding state of the federation on 1 January 1901. Its geography ranges from tropical rainforests and the Great Barrier Reef to interior deserts, earning the nickname the Sunshine State.

Which institutions developed the NUN-004 therapy?

The therapy originated from more than 25 years of research at The University of Queensland’s Queensland Brain Institute and is being advanced by the biotechnology company NuNerve.